{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:25Z","timestamp":1792801705987,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["a Grant-in-Aid for Scientific Research (B) (No. 21H03041)"],"award-info":[{"award-number":["a Grant-in-Aid for Scientific Research (B) (No. 21H03041)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["a Grant-in-Aid for Scientific Research (B) (No. 23H03018)"],"award-info":[{"award-number":["a Grant-in-Aid for Scientific Research (B) (No. 23H03018)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["a Grant-in-Aid for Research Activity Start-up (No. 19K24023)"],"award-info":[{"award-number":["a Grant-in-Aid for Research Activity Start-up (No. 19K24023)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["a Grant-in-Aid for Young Scientists (20K17954)"],"award-info":[{"award-number":["a Grant-in-Aid for Young Scientists (20K17954)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"a research grant from the Takeda Science Foundation","id":[{"id":"https:\/\/ror.org\/02y123g31","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"the Japanese Ministry of Education, Science, Sports, Culture and Technology","doi-asserted-by":"crossref","award":["JSPS KAKENHI grants No. 16H06277"],"award-info":[{"award-number":["JSPS KAKENHI grants No. 16H06277"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"the Japanese Ministry of Education, Science, Sports, Culture and Technology","doi-asserted-by":"crossref","award":["16H06279"],"award-info":[{"award-number":["16H06279"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although recent molecular analyses revealed that sporadic meningiomas have various genetic, epigenetic, and transcriptomic profiles, meningioma in patients with neurofibromatosis type 2 (NF2) have not been fully elucidated. This study investigated meningiomas' clinical, histological, and molecular characteristics in NF2 patients. A long-term retrospective follow-up (13.5\u2009\u00b1\u20095.5\u00a0years) study involving total 159 meningiomas in 37 patients with NF2 was performed. Their characteristics were assessed using immunohistochemistry (IHC), bulk-RNA sequencing, and copy number analysis. All variables of meningiomas in patients with NF2 were compared with those in 189 sporadic\n                    <jats:italic>NF2<\/jats:italic>\n                    -altered meningiomas in 189 patients. Most meningiomas in NF2 patients were stable, and the mean annual growth rate was 1.0\u2009\u00b1\u20091.8 cm\n                    <jats:sup>3<\/jats:sup>\n                    \/year. Twenty-eight meningiomas (17.6%) in 25 patients (43.1%) were resected during the follow-up period. WHO grade I meningiomas in patients with NF2 were more frequent than in sporadic\n                    <jats:italic>NF2<\/jats:italic>\n                    -altered meningiomas (92.9% vs. 80.9%). Transcriptomic analysis for patients with NF2\/sporadic\n                    <jats:italic>NF2<\/jats:italic>\n                    -altered WHO grade I meningiomas (n\u2009=\u200914 vs. 15, respectively) showed that tumours in NF2 patients still had a higher immune response and immune cell infiltration than sporadic\n                    <jats:italic>NF2<\/jats:italic>\n                    -altered meningiomas. Furthermore, RNA-seq\/IHC-derived immunophenotyping corroborated this enhanced immune response by identifying myeloid cell infiltration, particularly in macrophages. Clinical, histological, and transcriptomic analyses of meningiomas in patients with NF2 demonstrated that meningiomas in NF2 patients showed less aggressive behaviour than sporadic\n                    <jats:italic>NF2<\/jats:italic>\n                    -altered meningiomas and elicited a marked immune response by identifying myeloid cell infiltration, particularly of macrophages.\n                  <\/jats:p>","DOI":"10.1186\/s40478-023-01645-3","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:02:28Z","timestamp":1695704548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Meningiomas in patients with neurofibromatosis type 2 predominantly comprise \u2018immunogenic subtype\u2019 tumours characterised by macrophage infiltration"],"prefix":"10.1186","volume":"11","author":[{"given":"Yu","family":"Teranishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6369-3391","authenticated-orcid":false,"given":"Satoru","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakatochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiichiro","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DGR Evans","year":"2009","unstructured":"Evans DGR (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16","journal-title":"Orphanet J Rare Dis"},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z et al (2009) Neurofibromatosis type 2. Lancet 373:1974\u20131986","journal-title":"Lancet"},{"issue":"4","key":"1645_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmg.2010.085241","volume":"48","author":"MJ Smith","year":"2011","unstructured":"Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J et al (2011) Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutation: clear positional effect of mutations, absence of female severity effect on age at onset. J Med Genet 48(4):261\u2013265","journal-title":"J Med Genet"},{"key":"1645_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1086\/342716","volume":"71","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT et al (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715\u2013723","journal-title":"Am J Hum Genet"},{"key":"1645_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","volume":"52","author":"A Hexter","year":"2015","unstructured":"Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ et al (2015) Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 52:699\u2013705","journal-title":"J Med Genet"},{"issue":"5","key":"1645_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3171\/2020.3.JNS193230","volume":"134","author":"D Lewis","year":"2020","unstructured":"Lewis D, Donofrio CA, O\u2019Leary C, Li KL, Zhu X, Williams R et al (2020) The microenvironment in sporadic and neurofibromatosis type II\u2013related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 134(5):1419\u20131429","journal-title":"J Neurosurg"},{"key":"1645_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/00006123-199704000-00007","volume":"40","author":"M Samii","year":"1997","unstructured":"Samii M, Matthies C, Tatagiba M (1997) Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696\u2013705","journal-title":"Neurosurgery"},{"key":"1645_CR8","first-page":"274","volume":"49","author":"DE Brackmann","year":"2001","unstructured":"Brackmann DE, Fayad JN, Slattery WH, Friedman RA, Day JD, Hitselberger WE et al (2001) Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 49:274\u2013280","journal-title":"Neurosurgery"},{"issue":"10","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/neuonc\/nor101","volume":"13","author":"M Peyre","year":"2011","unstructured":"Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O et al (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13(10):1125\u20131132","journal-title":"Neuro Oncol"},{"issue":"3","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11060-010-0339-x","volume":"99","author":"S Goutagny","year":"2010","unstructured":"Goutagny S, Kalamarides M (2010) Meningiomas and neurofibromatosis. J Neurooncol 99(3):341\u2013347","journal-title":"J Neurooncol"},{"issue":"5","key":"1645_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3171\/2020.3.JNS192382","volume":"134","author":"S Abi Jaoude","year":"2020","unstructured":"Abi Jaoude S, Peyre M, Degos V, Goutagny S, Parfait B, Kalamarides M (2020) Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. J Neurosurg 134(5):1377\u20131385","journal-title":"J Neurosurg"},{"issue":"8","key":"1645_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","volume":"14","author":"S Goutagny","year":"2012","unstructured":"Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O et al (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14(8):1090\u20131096","journal-title":"Neuro Oncol"},{"issue":"10","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jnen\/60.10.994","volume":"60","author":"A Perry","year":"2001","unstructured":"Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjeee R, Margraf L et al (2001) Aggressive phenotypic and genotypic features in pediatric and NF2- associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 60(10):994\u20131003","journal-title":"J Neuropathol Exp Neurol"},{"key":"1645_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3171\/jns.1997.87.4.0610","volume":"87","author":"J Antinheimo","year":"1997","unstructured":"Antinheimo J, Haapasalo H, Halite M, Tatagiba M, Thomas S, Brandis A et al (1997) Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610\u2013614","journal-title":"J Neurosurg"},{"issue":"6123","key":"1645_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin A, Cotney J, Ozduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077\u20131080","journal-title":"Science"},{"issue":"5","key":"1645_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DTW, Heilscher T, Schefzyk S et al (2017) DNA methylation\u2014based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682\u2013694","journal-title":"Lancet Oncol"},{"key":"1645_CR17","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1038\/s41598-021-86298-9","volume":"11","author":"A Okano","year":"2021","unstructured":"Okano A, Miyawaki S, Hongo H, Dofuku S, Teranishi Y, Takayanagi S et al (2021) Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11:6987","journal-title":"Sci Rep"},{"issue":"11","key":"1645_CR18","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/2159-8290.CD-20-0160","volume":"10","author":"BC Prager","year":"2020","unstructured":"Prager BC, Vasudevan HN, Dixit D, Bernatchez J, Wu Q, Wallace LC et al (2020) The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies. Cancer Discov 10(11):1722\u20131741","journal-title":"Cancer Discov"},{"issue":"3","key":"1645_CR19","first-page":"345","volume":"19","author":"J Boetto","year":"2017","unstructured":"Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M (2017) SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol 19(3):345\u2013351","journal-title":"Neuro Oncol"},{"issue":"7874","key":"1645_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597(7874):119\u2013125","journal-title":"Nature"},{"key":"1645_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D et al (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841\u2013846","journal-title":"J Med Genet"},{"key":"1645_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 88:87\u201392","journal-title":"Neurology"},{"issue":"10","key":"1645_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jmedgenet-2020-106973","volume":"58","author":"Y Teranishi","year":"2021","unstructured":"Teranishi Y, Miyawaki S, Hongo H, Dofuku S, Okano A, Takayanagi S et al (2021) Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J Med Genet 58(10):701\u2013711","journal-title":"J Med Genet"},{"issue":"43","key":"1645_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"1645_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7","journal-title":"BMC Bioinform"},{"key":"1645_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457","journal-title":"Nat Methods"},{"issue":"1","key":"1645_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Zicheng Hu, Butte AJ (2017) xCell\/digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220","journal-title":"Genome Biol"},{"key":"1645_CR28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Garcia WT et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat commun 4:2612","journal-title":"Nat commun"},{"issue":"17","key":"1645_CR29","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","volume":"25","author":"C Rapp","year":"2019","unstructured":"Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C et al (2019) Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas. Clin Cancer Res 25(17):5260\u20135270","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1645_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3171\/2016.9.JNS161669","volume":"127","author":"EJ Lee","year":"2017","unstructured":"Lee EJ, Kim JH, Park ES, Kim YH, Lee JK, Hong SH et al (2017) A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg 127(5):971\u2013980","journal-title":"J Neurosurg"},{"issue":"11","key":"1645_CR31","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/neuonc\/noab075","volume":"23","author":"J Yeung","year":"2021","unstructured":"Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T et al (2021) Targeting the CSF1\/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro Oncol 23(11):1922\u20131935","journal-title":"Neuro Oncol"},{"issue":"11","key":"1645_CR32","doi-asserted-by":"publisher","first-page":"443369","DOI":"10.1101\/2021.05.11.443369","volume":"05","author":"C Blume","year":"2021","unstructured":"Blume C, Dogan D, Schweizer L, Peyre M, Doll S, Picard D et al (2021) Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion. BioRxiv 05(11):443369. https:\/\/doi.org\/10.1101\/2021.05.11.443369","journal-title":"BioRxiv"},{"key":"1645_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649\u2013659","journal-title":"Nat Genet"},{"key":"1645_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-022-01051-9","volume":"14","author":"AZ Wang","year":"2022","unstructured":"Wang AZ, Bowman-Kirigin JA, Desai R, Kang LI, Patel PR, Patel B et al (2022) Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. Genome Med 14:49","journal-title":"Genome Med"},{"key":"1645_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","volume":"8","author":"EA Williams","year":"2020","unstructured":"Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG, Sharaf R et al (2020) Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8:171","journal-title":"Acta Neuropathol Commun"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01645-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:42:18Z","timestamp":1700394138000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01645-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board approved the study protocol of The University of Tokyo Hospital (G10026, G10028) and Nagoya University (2021-0280), and informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors report no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}